UNIGE document Scientific Article
previous document  unige:25053  next document
add to browser collection

Est-il opportun de prescrire des inhibiteurs de la phosphodiestérase pour traiter le prostatisme?

Published in Revue médicale suisse. 2011, vol. 7, no. 320, p. 2394-7
Abstract This October, the FDA has approved the use of phosphodiesterase inhibitors for the treatment of micurition symptoms due to benign prostatic hyperplasia, so as for erectile dysfunction. This decision is essentially based on the results of 2 studies that we discuss in this article. Although methodologically well designed, these works show that phosphodiesterase inhibitors decrease only weakly, but statistically sigificatively the micturition score of patients suffering from prostatism. Besides that, only one of these papers show a limited effect on a single objective micturitionnal parameter. According to the present knowledge, it appears judicious to prescribe tadalafil to treat benign prostatic hyperplasia symptoms of patients suffering simultaneously of a significant erectile dysfunction.
Keywords Erectile Dysfunction/drug therapy/etiologyHumansMalePhosphodiesterase Inhibitors/therapeutic useProstatic Hyperplasia/complications/drug therapyQuestionnaires
PMID: 22232868
Full text
Article (Published version) (501 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://rms.medhyg.ch/
Research group Groupe Iselin Christophe (urologie) (106)
(ISO format)
CAVIEZEL, Alessandro Reto, ISELIN, Christophe. Est-il opportun de prescrire des inhibiteurs de la phosphodiestérase pour traiter le prostatisme?. In: Revue médicale suisse, 2011, vol. 7, n° 320, p. 2394-7. https://archive-ouverte.unige.ch/unige:25053

419 hits

0 download


Deposited on : 2013-01-07

Export document
Format :
Citation style :